Heron Therapeutics, Inc.

Historical 13F Holders

Symbol
HRTX
CUSIP
427746102
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 427746102 since 12/18/2024, newest first.

Filer % of Class Filed
Adage Capital Management, L.P. 13G/A Amendment 1
0% 5/13/2026
Event 3/31/2026
Vanguard Group Inc 13G/A Amendment 1 0% 3/27/2026
Event 3/13/2026
Clearline Capital LP 13G/A Amendment 1
6.7% 2/17/2026
Event 12/31/2025
Vanguard Group Inc 13G 5.4% 1/30/2026
Event 12/31/2025
Clearline Capital LP 13G
5.3% 11/26/2025
Event 9/30/2025
Vanguard Group Inc 13G/A Amendment 6 4.6% 10/30/2025
Event 9/30/2025
Rubric Capital Management LP 13D/A Amendment 5
15.9% 10/17/2025
Event 10/15/2025
Rubric Capital Management LP 13D/A Amendment 4
17.5% 8/12/2025
Event 8/8/2025

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 14 1.08 M $354 k
2026 Q2 171 134 M $59.3 M
2026 Q1 174 157 M $126 M
2025 Q4 176 157 M $207 M
2025 Q3 177 154 M $194 M
2025 Q2 177 135 M $279 M
2025 Q1 172 125 M $275 M
2024 Q4 168 115 M $176 M
2024 Q3 178 122 M $243 M
2024 Q2 197 130 M $457 M
2024 Q1 170 120 M $332 M
2023 Q4 161 114 M $194 M
2023 Q3 145 118 M $122 M
2023 Q2 154 98.9 M $115 M
2023 Q1 165 108 M $163 M
2022 Q4 184 118 M $296 M
2022 Q3 194 122 M $516 M
2022 Q2 184 115 M $322 M
2022 Q1 204 109 M $621 M
2021 Q4 219 118 M $1.08 B
2021 Q3 207 108 M $1.16 B
2021 Q2 202 104 M $1.61 B
2021 Q1 212 91.1 M $1.48 B
2020 Q4 202 90.9 M $1.92 B
2020 Q3 192 90.9 M $1.35 B
2020 Q2 210 88.6 M $1.33 B
2020 Q1 218 92.8 M $1.10 B
2019 Q4 213 100 M $2.35 B
2019 Q3 198 91.4 M $1.69 B
2019 Q2 197 94.1 M $1.75 B
2019 Q1 218 93.0 M $2.27 B
2018 Q4 195 92.1 M $2.39 B
2018 Q3 218 88.7 M $2.81 B
2018 Q2 224 86.5 M $3.36 B
2018 Q1 176 82.0 M $2.26 B
2017 Q4 145 69.0 M $1.25 B
2017 Q3 119 63.4 M $1.02 B
2017 Q2 120 69.6 M $964 M
2017 Q1 111 71.8 M $1.08 B
2016 Q4 111 52.8 M $692 M
2016 Q3 106 51.3 M $883 M
2016 Q2 104 47.0 M $848 M
2016 Q1 115 45.0 M $855 M
2015 Q4 124 45.4 M $1.21 B
2015 Q3 122 46.3 M $1.13 B
2015 Q2 99 36.2 M $1.13 B
2015 Q1 73 26.4 M $385 M
2014 Q4 65 24.6 M $247 M
2014 Q3 59 24.4 M $203 M
2014 Q2 71 29.4 M $363 M
2014 Q1 40 20.8 M $289 M